Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circulating Tumor DNA to Predict Recurrence in Colon Cancer
NCT02997241Unknown
- Sponsor
- MyGenostics
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Randomised, open-label trial in colorectal cancer (CRC) (4 arms), sponsored by MyGenostics. Primary endpoint: Progression-Free Survival at 66 weeks. Status: unknown.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02997241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997241.